MARKET

AMGN

AMGN

Amgen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

225.08
+3.04
+1.37%
Closed 18:40 12/01 EST
OPEN
224.88
PREV CLOSE
222.04
HIGH
225.78
LOW
222.72
VOLUME
3.05M
TURNOVER
--
52 WEEK HIGH
264.97
52 WEEK LOW
177.05
MARKET CAP
131.03B
P/E (TTM)
18.15
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
New Advances in Treating Difficult Blood Cancers From Johnson & Johnson and Others
This coming weekend, doctors who treat blood disorders will convene virtually to discuss new treatments that are extending the lives of patients.
Barrons.com · 14h ago
World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19
Three members of the COVID R&D; Alliance - Amgen Inc. (NASDAQ: AMGN), Takeda Pharmaceutical Co. Ltd. (NYSE: TAK), and UCB (Euronext BR: UCB) - today announced the first patient enrolled in the COMMUNITY Trial (COVID-19 Multiple Agents and Modulators Unified Industry Members). COMMUNITY is a randomized, double-blind, placebo-controlled, adaptive platform trial that enables an array of therapeutic candidates to be studied in hospitalized COVID-19 patients.
PR Newswire · 1d ago
Amgen Highlights Upcoming Data Presentations At American Society of Hematology Meeting Dec. 5-8
Amgen (NASDAQ:AMGN) today announced several upcoming data presentations from its oncology and hematology pipeline and marketed product portfolio at the 62nd American Society of Hematology (ASH) Annual Meeting &
Benzinga · 1d ago
Amgen Announces New Data Being Presented At ASH 2020
Amgen (NASDAQ:AMGN) today announced several upcoming data presentations from its oncology and hematology pipeline and marketed product portfolio at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, Dec. 5-8, 2020.
PR Newswire · 1d ago
COVID R&D Alliance launches trial of Amgen, UCB, Takeda drugs
Amgen Inc, UCB SA and Takeda Pharmaceuticals Inc on Monday launched a global trial to identify whether any of three different drugs can reduce the severity of COVID-19 in hospitalized patients by moderating the immune system's response to the disease. The drugmakers are part of the COVID Research & Development Alliance, a group of more than 20 pharmaceutical and biotechnology companies cooperating to speed development of therapies for the disease that has killed more than 1.4 million people worldwide. The study initially will test whether Amgen’s psoriasis drug Otezla, Takeda’s experimental anti-inflammatory lanadelumab, and UCB's experimental immune system-inhibitor zilucoplan can prevent the body's own defenses from overreacting to the coronavirus, which can lead to serious, sometimes fatal, tissue and organ damage.
Reuters · 1d ago
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
The U.S. Food and Drug Administration's approval machinery churned out a lot of disappointments in November. Most of the negative verdicts were tied to difficulties the agency has had in inspecting facilities where investigational drugs are being manufactured, amid COVID-19-related restrictions.
Benzinga · 3d ago
Amgen (AMGN) Up 1.8% Since Last Earnings Report: Can It Continue?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 4d ago
Amgen To Present At The Evercore ISI Virtual HealthCONx Conference
Amgen (NASDAQ:AMGN) will present at the Evercore ISI Virtual HealthCONx Conference at 1:50 p.m. ET on Tuesday, Dec. 1, 2020. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
PR Newswire · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMGN. Analyze the recent business situations of Amgen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 29 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMGN stock price target is 252.54 with a high estimate of 304.00 and a low estimate of 185.00.
EPS
Institutional Holdings
Institutions: 2.67K
Institutional Holdings: 469.90M
% Owned: 80.71%
Shares Outstanding: 582.17M
TypeInstitutionsShares
Increased
826
16.89M
New
209
-139.55K
Decreased
768
23.04M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.98%
Pharmaceuticals & Medical Research
+0.62%
Key Executives
Chairman/Chief Executive Officer/President/Director
Robert Bradway
Chief Financial Officer/Executive Vice President
Peter Griffith
Executive Vice President
Murdo Gordon
Executive Vice President
David Reese
Executive Vice President
Esteban Santos
Senior Vice President/Chief Compliance Officer
Cynthia Patton
Senior Vice President/General Counsel/Secretary
Jonathan Graham
Senior Vice President/Director of Human Resources
Lori Johnston
Senior Vice President
David Piacquad
Chief Accounting Officer/Vice President - Finance
Linda Louie
Lead Director/Independent Director
Robert Eckert
Independent Director
Wanda Austin
Independent Director
Brian Druker
Independent Director
Gregory Garland
Independent Director
Fred Hassan
Independent Director
Charles Holley
Independent Director
Tyler Jacks
Independent Director
Ellen Kullman
Independent Director
Amy Miles
Independent Director
Ronald Sugar
Independent Director
R. Sanders Williams
Independent Director
Robert Williams
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
10/21/2020
Dividend USD 1.6
11/13/2020
07/23/2020
Dividend USD 1.6
08/14/2020
03/04/2020
Dividend USD 1.6
05/15/2020
12/11/2019
Dividend USD 1.6
02/13/2020
10/22/2019
Dividend USD 1.45
11/14/2019
08/02/2019
Dividend USD 1.45
08/14/2019
03/07/2019
Dividend USD 1.45
05/16/2019
12/07/2018
Dividend USD 1.45
02/14/2019
10/23/2018
Dividend USD 1.32
11/15/2018
07/31/2018
Dividend USD 1.32
08/16/2018
03/07/2018
Dividend USD 1.32
05/16/2018
12/12/2017
Dividend USD 1.32
02/14/2018
10/24/2017
Dividend USD 1.15
11/16/2017
07/28/2017
Dividend USD 1.15
08/15/2017
03/07/2017
Dividend USD 1.15
05/15/2017
12/20/2016
Dividend USD 1.15
02/13/2017
10/14/2016
Dividend USD 1
11/14/2016
07/22/2016
Dividend USD 1
08/15/2016
03/02/2016
Dividend USD 1
05/13/2016
12/15/2015
Dividend USD 1
02/11/2016
10/14/2015
Dividend USD 0.79
11/12/2015
07/28/2015
Dividend USD 0.79
08/13/2015
03/04/2015
Dividend USD 0.79
05/12/2015
12/17/2014
Dividend USD 0.79
02/10/2015
10/17/2014
Dividend USD 0.61
11/10/2014
07/25/2014
Dividend USD 0.61
08/12/2014
03/05/2014
Dividend USD 0.61
05/13/2014
12/13/2013
Dividend USD 0.61
02/11/2014
10/16/2013
Dividend USD 0.47
11/12/2013
07/26/2013
Dividend USD 0.47
08/14/2013
03/06/2013
Dividend USD 0.47
05/14/2013
12/13/2012
Dividend USD 0.47
02/11/2013
10/10/2012
Dividend USD 0.36
11/13/2012
07/19/2012
Dividend USD 0.36
08/14/2012
03/15/2012
Dividend USD 0.36
05/14/2012
12/15/2011
Dividend USD 0.36
02/13/2012
10/13/2011
Dividend USD 0.28
11/15/2011
07/28/2011
Dividend USD 0.28
08/16/2011
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Amgen, Inc. stock information, including NASDAQ:AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.